If there is something that the world of today really loves, it’s having a take on almost everything around us. We like it, if we get to express ourselves. While this creates a substantial chance of opinions clashing and leading to lengthy debates, it also creates an opening for us to gather a range of insights into something. The possibility of having a fresh voice within the micro-sphere of a particular topic adds a dynamic that has become somewhat common these days. The dynamic in question not only ensures that the objective is achieved in the most comprehensible of ways, but it also makes sure that there is left an element for further improvement, if an advancement is to take place. That’s largely how we transformed the role of technology in our lives. What started as just one bold creation has now become synonymous to our present, and it looks fairly poised to retain this title for the future as well.
Our ability to take risks and presenting our takes on a wide spectrum of things has created a growth-oriented atmosphere all around us, and this reinventing the wheel has paid off big-time, especially in the field of medicine. The amount of benefit healthcare sector has reaped from the establishment of technology is nothing short of humongous. A sector that was once very limited in its options now has a whole assortment of things that can alter your life for the better, and there seems to be a new entrant on the cards.
For years, breast cancer has been a tricky ground to tread for the doctors. There were medications for taking away the hormones that were feeding the growth of tumor, but there was required a ‘fresh take’. Arvinas’ approach to breast cancer treatment might prove to be just that. Arvinas’ experimental therapy, ARV-471, a part of new type of medicines, is designed to leverage cell’s in-built system for getting rid of old or damaged proteins that are thought of as feeders to diseases like cancer. Even though many biotech companies are developing protein degradation drugs, Arvinas is the first one to focus solely on breast cancer. The potential of their treatment is testified by the $1 billion investment they got from pharmacy conglomerate, Pfizer. Pfizer has committed the amount in return for a share in developing and commercializing of this therapy.
